Company news
Prescient Therapeutics Limited (ASX:PTX) news
Prescient Therapeutics Limited news releases on 6ix. Latest, Oct 28, 2016: September 2016 Appendix 4C - Quarterly
Press releases — page 4
September 2016 Appendix 4C - Quarterly
October 28, 2016
First patient at Moffitt dosed in Phase 1b/2 breast trial
September 26, 2016
Appendix 4E and 2016 Annual Report
August 31, 2016
USPTO Grants Allowances for Two PTX-200 Patents
August 4, 2016
Change to exercise price of options
July 20, 2016
June 2016 Appendix 4C - Quarterly
July 19, 2016
Yale Joins PTXs Phase 1b/2 AML Clinical Trial
June 15, 2016
Replacement Entitlement Offer Prospectus
June 3, 2016
Offer Document
May 18, 2016
PTX Secures $7.0M Capital Raising
May 17, 2016
March 2016 Appendix 4C - Quarterly
April 21, 2016
Executive Management Change
March 30, 2016
PTX-200 Breast Cancer Trial Progresses
February 16, 2016
Steven Yatomi-Clarke Appointed CEO
February 15, 2016
December 2015 Appendix 4C - Quarterly
February 11, 2016
FDA Allows PTX IND for Leukemia Phase Ib & II Trials
February 10, 2016